search
pharmaceutical industry
Trends
- 1European Capital Backs Colombian Biotech Firm for 250 Million Vaccines▼Europe Injects Capital into Colombian Biotech Firm to Produce 250 Million Vaccines
European investors are injecting capital into a Colombian biotechnology company with plans to produce 250 million vaccines. The deal positions Colombia as a growing player in global vaccine manufacturing and reflects Europe's interest in diversifying pharmaceutical production capacity beyond its borders, though details on the funding amount and timeline remain limited.
- 2
A new EU report warns that pharmaceutical rules under debate in Brussels could make it harder for patients to access medicines. Concerns centre on provisions said to affect availability of treatments across member states, with patient groups and industry watching closely as the EU's pharmaceutical legislation reform moves forward.
- 3
Anthropic has established its own wet laboratory as it expands its AI-driven drug discovery programme, according to Reuters. The lab will let the company test biological hypotheses generated by its AI models in real experiments. Observers see it as a notable step for an AI firm moving from software into hands-on biology and pharmaceutical research.
- 4Biosimilars Sector Poised for M&A Shake-Up as Patent Cliff Looms●Biosimilars at an Inflection Point: How Regulatory Reform, a Maturing Patent Framework and a Looming Patent Cliff Are Reshaping M&A
Legal and industry analysts say the biosimilars market has reached an inflection point, with regulatory reform, a maturing patent litigation framework and an approaching wave of major biologic patent expirations reshaping merger and acquisition strategy. Commentators expect pharmaceutical companies to pursue deals to capture market share as blockbuster biologics lose exclusivity and cheaper biosimilar competition intensifies.